New osteoarthritis drug APPA-1 passes first safety check in small study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PART A: 1. Written informed consent 2. Between 18 and 75 years of age, inclusive 3. Of any ethnic origin 4. Healthy male subjects (groups A1 to A4) 5. Healthy female subjects (group A5) 6. BMI between 18.0 to 35.0 kg/m2 7. In good health as defined by medical history (including confirmation from GP), physical examination, vital signs assessment, 12 lead ECG and clinical laboratory evaluation. PART B: 1. Written informed consent 2. Between 18 and 75 years of age inclusive 3. Of any ethnic origin 4. Male or female subjects with a diagnosis of osteoarthritis fulfilling the American College of Rheumatology (ACR) criteria for diagnosis 5. BMI between 18.0 to 35.0 kg/m2 Exclusion Criteria: PART A: 1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use appropriate contraception or to refrain from donating sperm from the time of dosing until 3 months after the last dose of study drug. 2. Female subjects of childbearing potential not in agreement to use two highly effective methods of contraception, or to refrain from donating ova, from the time of screening until 28 days after the Follow Up Visit. 3. Female subjects who are pregnant or currently lactating 4. Donated blood in the 3 months prior to screening, plasma in the 7 days prior to screening, platelets in the 6 weeks prior to screening 5. Consume more than 28 units of alcohol per week if male, or 21 units of alcohol per week if female or any significant history of alcohol / substance misuse as determined by the investigator 6. Unwilling to abstain from vigorous exercise for 48 hours prior to any study visit 7. Unwilling to abstain from alcohol for 48 hours prior to any study visit 8. Tobacco smoking within 30 days of first dose, including use of e-cigarettes and not willing to abstain from smoking until after study involvement. 9. Received any medication, including St John's Wort, known to chronically alter drug absorption or elimination within 30 days prior to first dose administration unless in the opinion of the investigator it will not interfere with study procedures or compromise safety. 10. Received any prescribed systemic or topical medication within 14 days prior to the first dose administration (with the exception of the OCP) 11. Received any non-prescribed systemic or topical medication, herbal remedy or vitamin / mineral supplementation within 14 days prior to the first dose administration (with the exception of paracetamol). 12. Subjects who have any abnormality of vital signs prior to the first dose administration that, in the opinion of the investigator, would increase the risk of participating in the study 13. Subjects who have any clinically significant abnormal physical examination finding 14. Subjects who have any clinically significant 12 lead ECG abnormality that, in the opinion of the investigator, would increase the risk of participating in the study 15. Subjects who have, or have any history of, any clinically significant cardiovascular, respiratory, gastrointestinal, neurological, psychiatric, metabolic, endocrine, renal, hepatic, haematological or other major disorder as determined by the investigator 16. Subjects with International Normalised Ratio (INR) \> 1.3 17. Subjects who have any clinically significant allergy or allergic condition as determined by the investigator (with the exception of non-active hay fever) 18. Subjects who have any clinically significant abnormal laboratory safety results as determined by the investigator with specific exclusions of any AST or ALT greater than or equal to 1.5 times ULN at screening or day -1; total bilirubin \> ULN (Gilbert's syndrome is acceptable) 19. Subjects who have hepatitis B or C or are carriers of HBsAg or are carriers of HCV Ab or are positive for HIV 1/2 antibodies. 20. Subjects who have a positive alcohol breath test or a positive urine drug screen ( a repeat assessment is acceptable) 21. Subjects who are still participating in another clinical study or who have participated in a clinical study involving administration of an investigational product in the 3 months (or 5 half-lives, whichever is longer) prior to first dose administration 22. Subjects who have previously received APPA-1 or its constituent parts within 3 months of receiving first dose 23. Subjects who, in the opinion of the investigator, should not participate in this study. PART B: 1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use appropriate contraception or to refrain from donating sperm from the time of dosing until 3 months after the last dose of study drug. 2. Female subjects of childbearing potential not in agreement to use two highly effective methods of contraception, or to refrain from donating ova, from the time of screening until 28 days after the Follow Up Visit. 3. Female subjects who are pregnant or currently lactating 4. Donated blood in the 3 months prior to screening, plasma in the 7 days prior to screening, platelets in the 6 weeks prior to screening 5. Consume more than 28 units of alcohol per week if male, or 21 units of alcohol per week if female or any significant history of alcohol / substance misuse as determined by the investigator 6. Unwilling to abstain from vigorous exercise for 48 hours prior to any study visit 7. Unwilling to abstain from alcohol for 48 hours prior to any study visit 8. Tobacco smoking within 30 days of first dose, including use of e-cigarettes and not willing to abstain from smoking until after study involvement 9. Received any medication, including St John's Wort, known to chronically alter drug absorption or elimination within 30 days prior to first dose administration unless in the opinion of the investigator it will not interfere with study procedures or compromise safety. 10. Received and prescribed systemic or topical medication within 14 days prior to the first dose administration unless in the opinion of the investigator it will not interfere with study procedures or compromise safety and has been at stable dose for at least two weeks prior to screening. 11. Received any non-prescribed systemic or topical medication, herbal remedy or vitamin / mineral supplementation within 14 days prior to the first dose administration unless in the opinion of the investigator it will not interfere with study procedures or compromise safety. 12. Subjects who have any abnormality of vital signs prior to the first dose administration that, in the opinion of the investigator, would increase the risk of participating in the study 13. Subjects who have any clinically significant abnormal physical examination finding 14. Subjects who have any clinically significant 12 lead ECG abnormality that, in the opinion of the investigator, would increase the risk of participating in the study 15. Subjects who have any clinically significant medical history in the opinion of the investigator: stable, well controlled conditions such as hypertension, dyslipidaemia, type 2 diabetes (controlled by diet, exercise and/or oral medications), asthma (controlled by inhaled corticosteroids and or beta-2 agonists) etc. are acceptable 16. Subjects who have had recent (\<3 months) surgery or are scheduled to have any surgical procedure in the study period 17. Subjects who have any clinically significant allergy or allergic condition as determined by the investigator (with the exception of non-active hay fever) 18. Subjects who have any clinically significant abnormal laboratory safety results as determined by the investigator with specific exclusions of any AST or ALT greater than or equal to 1.5 times ULN at screening or day -1; total bilirubin \> ULN (Gilbert's syndrome is acceptable) 19. Subjects who have hepatitis B or C or are carriers of HBsAg or are carriers of HCV Ab or are positive for HIV 1/2 antibodies. 20. Subjects who have a positive alcohol breath test or a positive urine drug screen ( a repeat assessment is acceptable) 21. Subjects who are still participating in another clinical study or who have participated in a clinical study involving administration of an investigational product in the 3 months (or 5 half-lives, whichever is longer) prior to first dose administration 22. Subjects who have previously received APPA-1 or its constituent parts within 3 months of receiving first dose. 23. Subjects who, in the opinion of the investigator, should not participate in this study.